Approval marks a major step forward in proactive care for adults and children living with, or at risk of progression in Type 1 diabetes

Dubai, UAE, July 14, 2026: Sanofi today announced that UAE health authorities have approved expanded indications for an immunomodulatory therapy in Type 1 diabetes, marking a significant milestone in the evolution of care for one of the most complex autoimmune conditions affecting children, adolescents, and adults.